Palvella Therapeutics completed a Phase 3 trial for QTORIN™ rapamycin, targeting a rare genetic disease, with results expected in 2026. Top-line results from the SELVA trial are expected in the first ...

Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...

Aging-US is dedicated to advancing our understanding of the biological mechanisms that drive aging and the development of age-related diseases. Our mission is to serve as a platform for high-quality ...

The hype around the off-label use of the immunosuppressant rapamycin to prevent aging and increase longevity could be unfounded. This is the warning of researchers who have critically explored ...

100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) ...

Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved therapies and an estimated more than 50,000 diagnosed patients in the U.S.

The longevity and bio-hacking sector of medicine is known to be highly experimental, with a lot being pushed by fitness and health influencers that still requires significant testing. Also Read | ...

The anti-aging drug Rapamycin has the same life-extending effect as eating less, according to new research from the University of East Anglia and University of Glasgow. Dietary restriction has long ...

For centuries, humans have searched for ways to extend life. Alchemists never found the philosopher’s stone, but scientists have consistently shown that a longer life can be attained by eating less – ...